These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer. Shariat S; Badiee A; Jalali SA; Mansourian M; Yazdani M; Mortazavi SA; Jaafari MR Cancer Lett; 2014 Dec; 355(1):54-60. PubMed ID: 25224570 [TBL] [Abstract][Full Text] [Related]
4. Nanoliposomes carrying HER2/neu-derived peptide AE36 with CpG-ODN exhibit therapeutic and prophylactic activities in a mice TUBO model of breast cancer. Barati N; Nikpoor AR; Razazan A; Mosaffa F; Badiee A; Arab A; Gholizadeh Z; Behravan J; Jaafari MR Immunol Lett; 2017 Oct; 190():108-117. PubMed ID: 28736158 [TBL] [Abstract][Full Text] [Related]
5. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice. Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014 [TBL] [Abstract][Full Text] [Related]
6. Effective induction of CD8+ T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Li WM; Dragowska WH; Bally MB; Schutze-Redelmeier MP Vaccine; 2003 Jul; 21(23):3319-29. PubMed ID: 12804863 [TBL] [Abstract][Full Text] [Related]
7. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice. Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808 [TBL] [Abstract][Full Text] [Related]
8. Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids. Yazdani M; Jalali SA; Badiee A; Shariat S; Mansourian M; Arabi L; Abbasi A; Saberi Z; Jaafari MR Curr Drug Deliv; 2017; 14(4):492-502. PubMed ID: 27411392 [TBL] [Abstract][Full Text] [Related]
9. A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice. Arab A; Behravan J; Razazan A; Gholizadeh Z; Nikpoor AR; Barati N; Mosaffa F; Badiee A; Jaafari MR J Drug Target; 2018 Apr; 26(4):365-372. PubMed ID: 28972792 [TBL] [Abstract][Full Text] [Related]
10. Preparation of nanoliposomes containing HER2/neu (P5+435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer. Naghibi L; Yazdani M; Momtazi-Borojeni AA; Razazan A; Shariat S; Mansourian M; Arab A; Barati N; Arabsalmani M; Abbasi A; Saberi Z; Badiee A; Jalali SA; Jaafari MR PLoS One; 2020; 15(12):e0243550. PubMed ID: 33301467 [TBL] [Abstract][Full Text] [Related]
11. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. Miconnet I; Koenig S; Speiser D; Krieg A; Guillaume P; Cerottini JC; Romero P J Immunol; 2002 Feb; 168(3):1212-8. PubMed ID: 11801657 [TBL] [Abstract][Full Text] [Related]
12. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs. Mochizuki S; Morishita H; Kobiyama K; Aoshi T; Ishii KJ; Sakurai K J Control Release; 2015 Dec; 220(Pt A):495-502. PubMed ID: 26562685 [TBL] [Abstract][Full Text] [Related]
13. Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model. Razazan A; Behravan J; Arab A; Barati N; Arabi L; Gholizadeh Z; Hatamipour M; Reza Nikpoor A; Momtazi-Borojeni AA; Mosaffa F; Ghahremani MH; Jaafari MR PLoS One; 2017; 12(10):e0185099. PubMed ID: 29045460 [TBL] [Abstract][Full Text] [Related]
14. Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. Yan W; Chen W; Huang L J Control Release; 2008 Aug; 130(1):22-8. PubMed ID: 18554742 [TBL] [Abstract][Full Text] [Related]
15. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen. Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100 [TBL] [Abstract][Full Text] [Related]
16. The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo. Tian Y; Li M; Yu C; Zhang R; Zhang X; Huang R; Lu L; Yuan F; Fan Y; Zhou B; Men K; Xu H; Yang L Oncotarget; 2017 Jul; 8(28):45951-45964. PubMed ID: 28515346 [TBL] [Abstract][Full Text] [Related]
17. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. Xu Z; Ramishetti S; Tseng YC; Guo S; Wang Y; Huang L J Control Release; 2013 Nov; 172(1):259-265. PubMed ID: 24004885 [TBL] [Abstract][Full Text] [Related]
18. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development. Bayyurt B; Tincer G; Almacioglu K; Alpdundar E; Gursel M; Gursel I J Control Release; 2017 Feb; 247():134-144. PubMed ID: 28069554 [TBL] [Abstract][Full Text] [Related]
19. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer. Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473 [TBL] [Abstract][Full Text] [Related]
20. Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity. Stern BV; Boehm BO; Tary-Lehmann M J Immunol; 2002 Jun; 168(12):6099-105. PubMed ID: 12055220 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]